WHO Technical Advisory Group recommends mRNA-1469 for inclusion in efficacy study following encouraging Phase 1 ...

Even if the company's vaccine obtains approval, producing it at scale could be a big challenge.

Moderna said its vaccine to protect against ebola was recommended to advance into a Phase 2/3 trial in Congo. Pending regulatory approval, Moderna's mRNA-1469 vaccine will be tested to prevent ...

Moderna shares climb 6.8% on myeloma and Ebola vaccine updates, but quarterly results due Nov 6 will test the business behind ...

Moderna shares rose 8.8% to $248.63 after mRNA-1469 advanced toward Phase 2/3 trials in the DRC targeting Bundibugyo ...

Moderna (MRNA) will advance its investigational mRNA-1469 vaccine candidate against Bundibugyo ebolavirus toward a phase 2/3 efficacy study in the Democratic Republic of the Congo ...

Moderna, Inc. (NASDAQ: MRNA) announced that its investigational mRNA vaccine candidate, mRNA-1469, targeting Bundibugyo ebolavirus (BDBV), has been recommended to advance into a Phase 2/3 efficacy ...

Moderna has received FDA approval for a new flu vaccine designed for adults ages 50 and older. Learn more about this new ...

Key TakeawaysModerna shares jumped 8% after its myeloma therapy, mRNA-2808, showed four confirmed responses among 11 heavily pretreated patients. The data shows Moderna’s mRNA can get the body to make ...

ChAdOx1 BDBV, mRNA-1469 vaccines designed specifically for Bundibugyo virus in Congo as outbreak has killed 5,000, infected ...

Moderna's intismeran posted strong Phase 3 melanoma results, but patient-specific manufacturing that can take six weeks per ...

Personalized mRNA vaccines are enabling long-term remission in some stage II pancreatic cancer patients by reprogramming the ...